Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.37%
- Poor long term growth as Net Sales has grown by an annual rate of 57.40% and Operating profit at -0.88% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
With ROE of 2.9, it has a Very Expensive valuation with a 4.3 Price to Book Value
Falling Participation by Institutional Investors
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,137 Cr (Small Cap)
86.00
40
0.00%
0.49
2.88%
4.43
Total Returns (Price + Dividend) 
Sai Parenteral's for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Sai Parenterals Ltd is Rated Strong Sell
Sai Parenterals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 November 2026, reflecting a comprehensive assessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 14 November 2026, providing investors with the latest perspective on the company’s position.
Read More
Sai Parenterals Ltd Hits Intraday Low Amid Price Pressure on 2 Nov 2026
Sai Parenterals Ltd experienced a notable intraday decline on 2 Nov 2026, with the stock touching a low of Rs 484.6, marking a 6.99% drop from its previous close. This downturn occurred despite a positive start to the day and contrasted with broader market gains, reflecting immediate pressures on the stock within the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17-Nov-2026 | Source : BSEPress Release by Sai Parenterals Limited
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday 16Th November 2026
16-Nov-2026 | Source : BSEOutcome of Board Meeting held on Monday 16th November 2026
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
07-Nov-2026 | Source : BSEcall conducted on Monday the 2nd day of November 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.3%)
Held by 11 FIIs (2.85%)
Vijitha Gorrepati (28.91%)
Bhaskara Rao Bollineni (4.56%)
28.44%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 0.25% vs -7.06% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -26.91% vs -10.75% in Jun 2026
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 133.58% vs 6.08% in Mar 2025
YoY Growth in year ended Mar 2026 is -1.18% vs 71.38% in Mar 2025